AR102973A1 - Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende - Google Patents

Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende

Info

Publication number
AR102973A1
AR102973A1 ARP150104041A ARP150104041A AR102973A1 AR 102973 A1 AR102973 A1 AR 102973A1 AR P150104041 A ARP150104041 A AR P150104041A AR P150104041 A ARP150104041 A AR P150104041A AR 102973 A1 AR102973 A1 AR 102973A1
Authority
AR
Argentina
Prior art keywords
compound
pharmaceutical composition
trans
preparation
estilbene
Prior art date
Application number
ARP150104041A
Other languages
English (en)
Spanish (es)
Inventor
M Frey Steven
H Smith Susan
Cote-Sierra Javier
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of AR102973A1 publication Critical patent/AR102973A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP150104041A 2014-12-12 2015-12-11 Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende AR102973A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462090908P 2014-12-12 2014-12-12

Publications (1)

Publication Number Publication Date
AR102973A1 true AR102973A1 (es) 2017-04-05

Family

ID=55025296

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150104041A AR102973A1 (es) 2014-12-12 2015-12-11 Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende

Country Status (11)

Country Link
US (1) US10376475B2 (OSRAM)
EP (1) EP3229840B1 (OSRAM)
JP (3) JP7313117B2 (OSRAM)
KR (1) KR102607222B1 (OSRAM)
AR (1) AR102973A1 (OSRAM)
AU (1) AU2015358910B2 (OSRAM)
CA (1) CA2970739C (OSRAM)
DK (1) DK3229840T5 (OSRAM)
ES (1) ES2829637T3 (OSRAM)
TW (1) TWI692357B (OSRAM)
WO (1) WO2016092493A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
SG11201708666RA (en) 2015-05-21 2017-12-28 Glaxosmithkline Ip Dev Ltd Topical pharmaceutical compositions
US20170231922A1 (en) * 2016-02-16 2017-08-17 Horizon GenoMed Therapeutics, Inc 3, 5-dihydroxy-4-isopropylstilbene (dhis) as miticidal agent and its therapeutic uses
IL274439B2 (en) 2017-11-10 2023-12-01 Dermavant Sciences GmbH Process for preparing tapinarof
US10967197B2 (en) 2018-08-29 2021-04-06 Azulite, Inc. Phototherapy devices and methods for treating truncal acne and scars
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
US20220054467A1 (en) * 2019-02-25 2022-02-24 Sol-Gel Technologies Ltd. Treatment of psoriasis with topical tapinarof-tazarotene combination compositions
WO2020194313A1 (en) * 2019-03-26 2020-10-01 Sol-Gel Technologies Ltd. Treatment of hidradenitis suppurativa with tapinarof compositions
US20220287990A1 (en) * 2019-07-24 2022-09-15 Sol-Gel Technologies Ltd. Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions
WO2021059281A1 (en) * 2019-09-26 2021-04-01 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
JP2023503132A (ja) * 2019-11-24 2023-01-26 ソル － ゲル テクノロジーズ リミテッド タピナロフおよびｐｄｅ４阻害剤を含む局所用組成物による皮膚障害の治療
CN116265421B (zh) * 2021-12-17 2024-01-02 上海泽德曼医药科技有限公司 用于预防或治疗中枢神经系统相关疾病的化合物
WO2023109859A1 (zh) * 2021-12-15 2023-06-22 上海泽德曼医药科技有限公司 二苯乙烯类化合物及其在用于预防和/或治疗中枢神经系统相关疾病中的应用
WO2024050431A2 (en) * 2022-08-30 2024-03-07 Dermavant Sciences GmbH Tapinarof and analogs thereof for use in treating ahr mediated diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003695A1 (en) 1993-07-27 1995-02-09 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria xenorhabdus and photorhabdus spp.
US5747482A (en) * 1996-07-30 1998-05-05 Bernstein; Lawrence R. Methods and compositions to inhibit keratinocyte proliferation
US20030171429A1 (en) 1999-12-06 2003-09-11 Genhui Chen Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxyltilbenes and novel stilbene derivatives and analogues
WO2004031117A1 (en) * 2000-10-06 2004-04-15 Welichem Biotech Inc. Novel bioactive diphenyl ethene compounds and their therapeutic applications
US7321050B2 (en) 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
FR2917427B1 (fr) * 2007-06-18 2009-08-21 Galderma Res & Dev Inhibiteurs de tace dans le traitement de l'acne
US9308239B2 (en) * 2008-02-26 2016-04-12 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US20100003315A1 (en) * 2008-07-02 2010-01-07 Willeford Kenneth L Method and Composition for the Treatment of Skin Conditions
CN101531571B (zh) 2009-04-17 2013-03-20 河北科技大学 六次甲基四胺氧化合成二苯乙烯类化合物的方法
CN101633606B (zh) 2009-08-13 2014-08-27 河北科技大学 盐酸非均相氯代合成茋类化合物的方法
CN101648851B (zh) 2009-09-03 2012-10-10 河北科技大学 (e)-3,5-二羟基-4-异丙基二苯乙烯的清洁制备方法
CN101830764A (zh) 2010-05-05 2010-09-15 河北科技大学 利用Pfitzner-moffatt氧化反应合成茋类化合物的方法
CN101838173A (zh) 2010-05-07 2010-09-22 河北科技大学 利用Kornblum氧化反应合成茋类化合物的方法
EP2723889B1 (en) * 2011-06-27 2019-11-06 Galderma Research & Development New th17 differentiation markers for acne and uses thereof

Also Published As

Publication number Publication date
CA2970739C (en) 2023-10-03
CA2970739A1 (en) 2016-06-16
EP3229840A1 (en) 2017-10-18
EP3229840B1 (en) 2020-09-09
JP2021152018A (ja) 2021-09-30
AU2015358910B2 (en) 2019-01-24
US10376475B2 (en) 2019-08-13
JP2017537936A (ja) 2017-12-21
TWI692357B (zh) 2020-05-01
DK3229840T5 (da) 2020-11-16
DK3229840T3 (da) 2020-11-09
JP2023123554A (ja) 2023-09-05
KR102607222B1 (ko) 2023-11-29
WO2016092493A1 (en) 2016-06-16
KR20170095928A (ko) 2017-08-23
TW201639548A (zh) 2016-11-16
AU2015358910A1 (en) 2017-06-29
JP7313117B2 (ja) 2023-07-24
ES2829637T3 (es) 2021-06-01
US20170360719A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2017009449A (es) Inhibidor jak.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
DOP2017000111A (es) Inhibidor de cinasa aurora a
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
AR103680A1 (es) Inhibidores selectivos de bace1
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.

Legal Events

Date Code Title Description
FC Refusal